Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

Delays in tax reform and infrastructure bills may lead to market 'hiccups' and lower entry points.
Readers want to know what to do with the two biotech names, which are headed in opposite directions.
These two large-cap drug giants should be core parts of any well-diversified portfolio.
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Biotech Buoyed by Deal Talk Real Money Pro($)

M&A activity is in a serious upswing, and here are some names to watch.
Macy's, American Outdoor Brands and Mattel may be value picks in a beaten-down sector.
We answer recent reader questions about three of the biotech stocks we regularly cover.

Oh Twitter! Real Money Pro($)

It has been great sitting in for Doug Kass over the past two days. There has been some lively conversation and it's fun to be around for a nice rally today. Twitter (TWTR) had one of its roughest days in quite a while and the stock is sinking toward irrelevancy. Cowen & Co. and Raymond James become the latest analyst firms to jump on the bandwagon and downgrade the shares. Tomorrow, I will be answering some recent questions in my Small Cap Mailbag in my column.
The market is maintaining and adding to its nice gains since our last update. Financials are very strong after Rep. Jeb Hensarling, chairman of the House Financial Services Committee, called the Consumer Financial Protection Bureau a rogue agency in a WSJ opinion piece today. I read the article this morning, and it's a well-written piece. It won't make Sen. Elizabeth Warren, D-Mass., happy, but the over-reaching by an unaccountable regulatory body looks headed for a dismantling, which would be good for the financial sector and the economy in my opinion.

Columnist Conversations

FIBOCALL: TGT certainly missed the mark We all know that TGT missed the mark, but let's see where support l...
On Friday NVDA opened with its second straight gap lower open as the steep pullback from the Jan/Feb highs con...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.